Systemic D3R-antagonism attenuates nigrostriatal neurodegeneration induced by MPTP. Inhibition of D3R-signaling favours activation of astrocytes with anti-inflammatory properties. D3R-antagonism reduces the motor impairment in a mouse model of Parkinson's disease. D3R-antagonism attenuates the acquisition of activated-morphology by microglia.